Pfizer To Further Cut Price For Prevenar 13 In Poorest Countries Through 2025

(RTTNews) - Pfizer Inc (PFE) on Monday announced new commitments aimed at ensuring the world's most poorest countries have access to its pneumococcal vaccine Prevenar 13 through Gavi, the Vaccine Alliance. Pfizer's commitments were announced during Gavi's pledging conference being held in Berlin, Germany, in support of Gavi's 2016 - 2020 strategy.

Pfizer announced a 20 cent reduction of its per-dose price for Prevenar 13, from $3.30 per-dose to $3.10 per dose for the new four-dose vial presentation, which is expected to be introduced under the Advanced Market Commitment (AMC) program in 2016.

Because of the practical constraints experienced by health workers operating in many Gavi countries, the new multi-dose presentation was developed for maximum efficiency, such as helping to address storage requirements and shipping costs in the field.

This new lower per- dose price will be extended to all Gavi eligible and Gavi graduated countries through 2025, continuing to ensure that even children in the most remote regions of the world can receive this life-saving immunization.

Pfizer said it is proud to partner with Gavi to achieve its ambitious goal - providing countries with the support needed to potentially immunize an additional 300 million of the world's poorest children against life-threatening diseases by 2020 and thus, potentially assisting in the prevention of more than five million premature deaths.